• Ardent Health Q2 2026 revenue fell 1.4% to $1.62 billion; net income attributable to shareholders dropped to $17 million from $73 million.
• GAAP diluted EPS slid to $0.12 from $0.52; non-GAAP adjusted EBITDA fell 32.3% to $115 million.
• Operating cash flow climbed 67% to $197 million, despite a 1% decline in admissions and a 2.9% drop in total surgeries.
• Results reflected tougher year-over-year comparisons after prior-year benefit from New Mexico state directed payments; volumes improved after an early June update.
• Reaffirmed full-year revenue guidance of $6.4 billion-$6.7 billion, maintaining non-GAAP adjusted EBITDA outlook of $485 million-$535 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardent Health Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.